Cracking The Code: Understanding Analyst Reviews For Merck & Co
Merck & Co (NYSE:MRK) underwent analysis by 10 analysts in the last quarter, revealing a spectrum of viewpoints…
Competitor Analysis: Evaluating Merck & Co And Competitors In Pharmaceuticals Industry
In the ever-evolving and intensely competitive business landscape, conducting a thorough company analysis is of utmost importance for…
Covid-19 Pharma Stars Continue Their Quest To Set New Standards In Cancer Treatment
AstraZeneca PLC (NASDAQ: AZN) kicked off the week by receiving approval from the U.S. Food and Drug Administration for its blockbuster cancer drug Imfinzi combined with chemotherapy being used as a treatment forpatients suffering from specific type of endometrial cancer.
FDA Approves Merck’s Pneumococcal Vaccine As First Shot Designed For Adults
The FDA has approved Merck's Capvaxive, the first pneumococcal conjugate vaccine for adults, protecting against 21 strains of bacteria. Additionally, Merck's Keytruda received FDA approval for advanced endometrial carcinoma.
Merck & Co Unusual Options Activity For June 14
Investors with a lot of money to spend have taken a bullish stance on Merck & Co (NYSE:MRK).…
How Is The Market Feeling About Merck & Co?
Merck & Co’s (NYSE:MRK) short percent of float has risen 8.11% since its last report. The company recently…
Nike, Merck, General Motors, And More: CNBC’s ‘Final Trades’
Liz Young of SoFi recommends Energy Select Sector SPDR Fund as her final trade on CNBC's Halftime Report. Jim Lebenthal of Cerity Partners picks General Motors, while Jason Snipe of Odyssey Capital Advisors chooses Merck. Stephanie Link of Hightower suggests Nike as her final trade.
Market Whales and Their Recent Bets on MRK Options
Whales with a lot of money to spend have taken a noticeably bullish stance on Merck & Co.…
Promising Trial Results Show New Standards In Cancer Treatment And Diagnostics Are On The Horizon
On Friday, Pfizer Inc (NYSE: PFE) revealed its drug for an advanced form of lung cancer showed promising long-term results in a late-stage trial. On Monday, Moderna (NASDAQ: MRNA) and Merck & Co (NYSE:
Comparative Study: Merck & Co And Industry Competitors In Pharmaceuticals Industry
In the fast-paced and highly competitive business world of today, conducting thorough company analysis is essential for investors…